Patient-Derived Amyloid Xenograft Model for ATTR Drug Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transgenic animal models for amyloidosis, particularly those for ATTR amyloidosis, fail to accurately replicate human amyloid deposition and toxicity, limiting their effectiveness in testing anti-amyloid drug efficacy and safety.
Innovation Solution
A patient-derived amyloid xenograft (PDAX) rodent model is developed by implanting amyloid transthyretin (ATTR) fibrils from human patients into non-transgenic rodents, allowing for the assessment of anti-amyloid drug efficacy through subcutaneous or other implantation methods, using antibodies like NI-301.37F1 to promote fibril clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If transgenic animal models are used to model ATTR amyloidosis, then the models can be genetically engineered to express human TTR mutations, but they fail to accurately replicate human amyloid deposition and toxicity
Solution Approach 1:
The patent uses patient-derived amyloid fibrils as a direct copy of human pathology, implanting actual human amyloid material into immunodeficient rodents. This bypasses the need for transgenic engineering while accurately replicating human amyloid deposition and toxicity, as the fibrils retain their native human conformation and pathogenic properties.
Solution Approach 2:
The patent introduces human amyloid fibrils as an intermediary element between human pathology and rodent testing. These fibrils serve as a bridge that transfers human disease characteristics into the rodent model without requiring genetic modification of the host animal, thereby achieving human-relevant pathology in a non-human system.
2Adaptability or versatility
If transgenic mouse models are used for drug testing, then the models can be engineered with human TTR mutations, but they show high variability depending on age, gender, genetic background and housing conditions
Solution Approach 1:
By copying actual human amyloid fibrils directly from patients into standardized immunodeficient rodents, the patent eliminates the variability inherent in transgenic models. The fibrils themselves carry the genetic information, allowing consistent implantation across genetically identical rodents regardless of age, gender, or housing conditions.
Solution Approach 2:
The patent separates the genetic variable (TTR mutation) from the host organism by extracting amyloid fibrils from human patients and implanting them into standardized rodents. This segmentation allows the genetic factor to be controlled through patient selection while the rodent host remains genetically uniform, reducing experimental variability.
3Adaptability or versatility
If transgenic animal models are used, then the models can express human TTR protein, but they show absence or rarity of ATTR amyloid deposits and absence of phenotypes mimicking patient symptoms
Solution Approach 1:
The patent directly copies human amyloid fibrils that already contain the misfolded TTR protein and associated pathology from patients. This approach bypasses the need for transgenic expression while ensuring accurate phenotypic representation, as the fibrils themselves embody the human disease state including all post-translational modifications and conformational characteristics.
Solution Approach 2:
Instead of engineering animals to express human protein and hope for amyloid formation, the patent inverts the approach by taking pre-formed human amyloid fibrils and implanting them into animals. This reversal guarantees phenotype accuracy by starting with confirmed human pathology rather than relying on spontaneous amyloidogenesis in transgenic models.
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
Provided are a patient-derived amyloid xenograft (PDAX) non-human animal model, uses and production methods thereof as well as methods comprising the model to determine/obtain anti- amyloid drugs suitable for the treatment of an amyloidosis or amyloid-related disease and methods and processes to characterize, validate, develop and/or quality control and manufacture such drugs.